Open AccessBlood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics
Author(s) -
Rodney M. Camire
Publication year - 2021
Publication title -
journal of thrombosis and thrombolysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.708
H-Index - 67
eISSN - 1573-742X
pISSN - 0929-5305
DOI - 10.1007/s11239-021-02456-w
Subject(s) - coagulation , coagulation cascade , medicine , hematology , thrombin , clotting factor , factor ix , thrombin generation , blood clotting , tissue factor , disease , computational biology , immunology , bioinformatics , biology , platelet
Blood coagulation factor X/Xa sits at a pivotal point in the coagulation cascade and has a role in each of the three major pathways (intrinsic, extrinsic and the common pathway). Due to this central position, it is an attractive therapeutic target to either enhance or dampen thrombin generation. In this brief review, I will summarize key developments in the molecular understanding of this critical clotting factor and discuss the molecular basis of FX deficiency, highlight difficulties in expressing recombinant factor X, and detail two factor X variants evaluated clinically.